CompletedNCT00194012
Aripiprazole compared with placebo for early bipolarity symptoms in children
About this title
Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder
Read the official source — NCT00194012Medication studyAges 5–17United States
Understand this study
Who was this study for?
Listed age limits: 5 years to 17 years.
- Listed locations
- ClevelandSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateAugust 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 62
- Sponsor
- University Hospitals Cleveland Medical Center
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 5 Years to 17 Years
- Official registry ID
- NCT00194012
- Official title
Show the full official title
Aripiprazole in At-Risk Children With Symptoms of Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cleveland
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University Hospitals Cleveland Medical Center, a university.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole and Placebo.
Who was this study for?
Listed age limits: 5 years to 17 years.
